<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719377</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-19POWME01</org_study_id>
    <nct_id>NCT04719377</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating the Effectiveness and Safety of the PowerMe Midline Catheter in the Chinese Population</brief_title>
  <official_title>A Prospective, Multi-center, Open-label, Randomized, Controlled Non-inferiority Clinical Trial Evaluating the Effectiveness and Safety of the PowerMe Midline Catheter Versus Traditional PIV in the Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effectiveness and the safety of the PowerMeTM Midline&#xD;
      Catheter in the Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, open-label, randomized, controlled, non-inferiority&#xD;
      clinical trial designed to evaluate the effectiveness and the safety of the PowerMeTM Midline&#xD;
      Catheter compared to PIVC in the Chinese population in order to support the product's&#xD;
      registration in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>PowerMe Midline</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptance of the overall performance of the IV catheter system</measure>
    <time_frame>up to 28 days</time_frame>
    <description>After the placement of the IV catheter system, the study nurse shall answer &quot;yes/no&quot; to the following questions:&#xD;
Can the IV catheter system vent the air properly;&#xD;
Can the IV catheter system be inserted and be placed in the blood vessel;&#xD;
Can the needle tube be withdrawn from the septum;&#xD;
After the removal of the IV catheter system, the study nurse shall answer &quot;yes/no&quot; to the following questions:&#xD;
Can the IV catheter system be removed properly;&#xD;
There is no leakage during the application of the IV catheter system (including the processes of venting, infusion, flushing and sealing, and indwelling).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of the first insertion of the catheter</measure>
    <time_frame>First day, during catheter insertion</time_frame>
    <description>Successful first insertion means the IV catheter system can be successfully inserted into the blood vessel on the first insertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indwelling time</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The retention time of the IV catheter system of each subject after successful insertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of good performance of the pinch clamp</measure>
    <time_frame>up to 28 days</time_frame>
    <description>If the pinch clamp can close and open the tubing properly, performance of the pinch clamp can be evaluated as &quot;good&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of catheter blockage</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The catheter system is blocked, causing the system to fail to infuse the fluid after it is connected to the infusion set/syringe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of accidental dislodgement</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Unintentional premature removal of the catheter from the vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of phlebitis</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Incidence of phlebitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Incidence of serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Catheterization</condition>
  <arm_group>
    <arm_group_label>Powerme midline catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powerme midline catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peripheral intravenous catheter</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>BD Pegusas peripheral intravenous catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>catheter placement</intervention_name>
    <description>catheter placement</description>
    <arm_group_label>Powerme midline catheter</arm_group_label>
    <arm_group_label>peripheral intravenous catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥18 years of age;&#xD;
&#xD;
          2. Inpatient with a need for intravenous infusion for an expected period of more than 4&#xD;
             days but no more than 28 days;&#xD;
&#xD;
          3. The veins in the upper limbs is suitable for puncture and catheterization of both the&#xD;
             investigational device and the control device;&#xD;
&#xD;
          4. Willing to provide written Informed Consent and complete the study per the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Coagulation disorder or active bleeding;&#xD;
&#xD;
          2. Skin injury, infection, or dermatosis at the site to be punctured;&#xD;
&#xD;
          3. History of radiotherapy, thrombosis, or vascular surgery; arteriovenous fistula or&#xD;
             phlebitis history at the area and/or vein to be catheterized;&#xD;
&#xD;
          4. History of mental illness;&#xD;
&#xD;
          5. End stage renal disease requires vein protection;&#xD;
&#xD;
          6. Conditions with decreased venous flow in the extremity, such as lymphedema of the arm,&#xD;
             etc.;&#xD;
&#xD;
          7. Infusions of vesicant or irritant drugs, hyperosmotic infusate (the osmotic pressure&#xD;
             &gt;900mOsm/L in this study), parenteral nutrition, etc., which are not suitable for&#xD;
             peripheral intravenous infusion (If other appropriate venous access is established for&#xD;
             the aforementioned infusates, the patient may be enrolled).&#xD;
&#xD;
          8. The evaluation of the upper limb veins is Grade II, the evaluation grade is as&#xD;
             following:&#xD;
&#xD;
               -  0 Veins are obviously bulged on the skin surface. The veins are touchable, thick,&#xD;
                  straight, soft, elastic and fixed.&#xD;
&#xD;
               -  I Veins are relatively full and faintly touchable. The veins are less elastic or&#xD;
                  slide easily.&#xD;
&#xD;
               -  II Veins are not full or collapsed and untouchable. The veins are hard or&#xD;
                  sliding. Phlebitis.&#xD;
&#xD;
          9. Self-reported being pregnant or lactating;&#xD;
&#xD;
         10. Other conditions that the investigator considers improper for the study;&#xD;
&#xD;
         11. Participating in another study or already enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuying Li, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoxia Zhu</last_name>
    <phone>+86-21- 2325 4853</phone>
    <email>justina.zhu@bd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoshan Shan</last_name>
    <email>xiaoshan.shan@bd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuying Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First General Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Xing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lili Hou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lan Xu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>midline</keyword>
  <keyword>overall performance</keyword>
  <keyword>indwelling time</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

